# Stoke Therapeutics Inc. (STOK) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $26.99, market value $1.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Stoke Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 63.4×**. Each dollar of revenue is priced at 63.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.0×**. The shares trade at 5.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -10.3%** (5-yr avg -13.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -809.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -3.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -2.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -49.7%**. Each dollar of assets produces -49.7% of profit.

## Growth
- **Revenue growth (1 yr): 404.5%** (3-yr 145.9%/yr). Revenue grew 404.5% over the last year.
- **EPS growth (1 yr): 92.7%**. Earnings per share rose 92.7%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 5.28** (quick 5.28). Current assets cover the next year's liabilities 5.28 times.
- **Altman Z-score: 18.08**. A Z-score of 18.08 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Stoke Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Stoke Therapeutics Inc.; the consensus is strong_buy, with an average price target of $46.38 (+72% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -11.9%** (YTD -16.6%, 3-mo -10.4%). The shares are down 11.9% over twelve months including dividends.
- **From 52-week high: -32.9%** (32.8% above the low). Trading 33% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.82** (volatility 57%). Beta of 0.82 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=STOK · Page: https://foliofundamentals.com/stocks/stok

Not investment advice.